Cardiovascular Systems (CSII) versus Its Rivals Head to Head Comparison

Cardiovascular Systems (NASDAQ: CSII) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its peers? We will compare Cardiovascular Systems to related businesses based on the strength of its profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Ratings

This is a breakdown of recent recommendations for Cardiovascular Systems and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiovascular Systems 1 2 3 1 2.57
Cardiovascular Systems Competitors 174 1131 2472 89 2.64

Cardiovascular Systems currently has a consensus target price of $34.25, suggesting a potential upside of 28.81%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 9.62%. Given Cardiovascular Systems’ higher possible upside, research analysts clearly believe Cardiovascular Systems is more favorable than its peers.


This table compares Cardiovascular Systems and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cardiovascular Systems -0.87% 0.88% 0.58%
Cardiovascular Systems Competitors -127.16% -36.40% -10.26%

Earnings and Valuation

This table compares Cardiovascular Systems and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Cardiovascular Systems $204.91 million $5.43 million -443.09
Cardiovascular Systems Competitors $827.23 million $159.49 million 36.68

Cardiovascular Systems’ peers have higher revenue and earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

74.5% of Cardiovascular Systems shares are held by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 3.3% of Cardiovascular Systems shares are held by insiders. Comparatively, 11.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Cardiovascular Systems has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500. Comparatively, Cardiovascular Systems’ peers have a beta of 1.06, meaning that their average share price is 6% more volatile than the S&P 500.


Cardiovascular Systems beats its peers on 8 of the 13 factors compared.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with's FREE daily email newsletter.

Leave a Reply